obinutuzumab + bendamustine + venetoclax

The combination of **obinutuzumab + bendamustine + venetoclax** (sometimes referred to as "BOV") is an investigational, multi-agent regimen studied primarily for the treatment of B-cell malignancies such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Obinutuzumab is a fully humanized type II anti-CD20 monoclonal antibody that induces B-cell depletion by targeting the CD20 antigen on B lymphocytes, resulting in direct cell death and immune-mediated cytotoxicity. Bendamustine is an alkylating agent that induces DNA crosslinking and cell death. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, a protein that prevents apoptosis in cancer cells; by blocking BCL-2, venetoclax promotes apoptosis of malignant cells. The combination aims to leverage complementary mechanisms—antibody-mediated immunity, direct cytotoxicity, and apoptosis induction—to enhance antitumor efficacy in B-cell lymphomas and leukemias. This combination has shown high complete response rates in clinical studies for untreated MCL, but increased toxicity (notably cytopenias and infections) compared to doublets, and is not a standard approved regimen in major guidelines as of the most recent studies[1][3].

Brand names

Venclexta + Bendamustine + Gazyva

Other names

BOVbendamustine + obinutuzumab + venetoclax